Skip to main content
SpringerLink
Log in

Response to: GCP III is not the “off-target” for urea-based PSMA-ligands

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Lee Z, Heston WD, Wang X, et al. GCP III is not the “off-target” for urea-based PSMA ligands. Eur J Nucl Med Mol Imaging. 2023.https://doi.org/10.1007/s00259-023-06265-6.

  2. Lucaroni L, Georgiev T, Prodi E, Puglioli S, Pellegrino C, Favalli N, Prati L, Manz MG, Cazzamalli S, Neri D, et al. Cross-reactivity to glutamate carboxypeptidase III causes undesired salivary gland and kidney uptake of PSMA-targeted small-molecule radionuclide therapeutics. Eur J Nucl Med Mol Imaging. 2023;50:957–61. https://doi.org/10.1007/s00259-022-05982-8.

    Article  CAS  PubMed  Google Scholar 

  3. Tykvart J, Schimer J, Jančařík A, Bařinková J, Navrátil V, Starková J, Šrámková K, Konvalinka J, Majer P, Šácha P. Design of highly potent urea-based, exosite-binding inhibitors selective for glutamate carboxypeptidase II. J Med Chem. 2015;58:4357–63.

    Article  CAS  PubMed  Google Scholar 

  4. Krall N, Pretto F, Mattarella M, Müller C, Neri D. A 99mTc-labeled ligand of carbonic anhydrase IX selectively targets renal cell carcinoma in vivo. J Nucl Med. 2016;57:943–9.

    Article  CAS  PubMed  Google Scholar 

  5. Millul J, Bassi G, Mock J, Elsayed A, Pellegrino C, Zana A, Dakhel Plaza S, Nadal L, Gloger A, Schmidt E, et al. An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications. Proc Natl Acad Sci USA. 2021;118:e2101852118.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Srinivasarao M, Galliford CV, Low PS. Principles in the design of ligand-targeted cancer therapeutics and imaging agents. Nat Rev Drug Discov. 2015;14:203–19.

    Article  CAS  PubMed  Google Scholar 

  7. Morris RT, Joyrich RN, Naumann RW, Shah NP, Maurer AH, Strauss HW, Uszler JM, Symanowski JT, Ellis PR, Harb WA. Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (<sup>99m</sup>Tc-etarfolatide)<sup>†</sup>. Ann Onc. 2014;25:852–8.

    Article  CAS  Google Scholar 

  8. Merkx RIJ, Lobeek D, Konijnenberg M, Jiménez-Franco LD, Kluge A, Oosterwijk E, Mulders PFA, Rijpkema M. Phase I study to assess safety, biodistribution and radiation dosimetry for (89)Zr-girentuximab in patients with renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2021;48:3277–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Version 22.0. Last update 22/12/07. https://www.proteinatlas.org/ENSG00000107159-CA9. Accessed 09.05.2023.

  10. Kulterer OC, Pfaff S, Wadsak W, Garstka N, Remzi M, Vraka C, Nics L, Mitterhauser M, Bootz F, Cazzamalli S, et al. A Microdosing Study with 99mTc-PHC-102 for the SPECT/CT imaging of primary and metastatic lesions in renal cell carcinoma patients. J Nucl Med. 2021;62:360.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Version 22.0. Last update 22/12/07. https://www.proteinatlas.org/ENSG00000086205-FOLH1. Accessed 09.05.2023.

  12. Version 22.0. Last update 22/12/07. https://www.proteinatlas.org/ENSG00000077616-NAALAD2. Accessed 09.05.2023.

  13. Pandit-Taskar N, O’Donoghue JA, Divgi CR, Wills EA, Schwartz L, Gönen M, Smith-Jones P, Bander NH, Scher HI, Larson SM, et al. Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. EJNMMI Res. 2015;5:28.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Weich A, Serfling SE, Yi H, Buck AK, Higuchi T, Werner RA. Complete remission upon peptide receptor radionuclide therapy in a G2 pancreatic neuroendocrine tumor. Clin Nucl Med. 2023;48:335–6.

    Article  PubMed  Google Scholar 

  15. Tönnesmann R, Meyer PT, Eder M, Baranski A-C. [177Lu]Lu-PSMA-617 salivary gland uptake characterized by quantitative in vitro autoradiography. Pharmaceuticals. 2019;12:18.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Rupp NJ, Umbricht CA, Pizzuto DA, Lenggenhager D, Töpfer A, Müller J, Muehlematter UJ, Ferraro DA, Messerli M, Morand GB, et al. First clinicopathologic evidence of a non–PSMA-related uptake mechanism for <sup>68</sup>Ga-PSMA-11 in salivary glands. J Nucl Med. 2019;60:1270–6.

    Article  CAS  PubMed  Google Scholar 

  17. Ruigrok EAM, van Vliet N, Dalm SU, de Blois E, van Gent DC, Haeck J, de Ridder C, Stuurman D, Konijnenberg MW, van Weerden WM, et al. Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy. Eur J Nucl Med Mol Imaging. 2021;48:1339–50.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Sara Puglioli for fruitful discussion.

Author information

Author notes

  1. Gabriele Bassi and Samuele Cazzamalli contributed equally to the manuscript.

Authors and Affiliations

  1. Small Molecule Therapeutics Department, Philochem AG, Libernstrasse 3, 8112, Otelfingen, Switzerland

    Gabriele Bassi, Samuele Cazzamalli, Sebastian Oehler, Laura Lucaroni, Tony Georgiev, Nicholas Favalli & Dario Neri

Authors
  1. Gabriele Bassi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Samuele Cazzamalli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sebastian Oehler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Laura Lucaroni
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tony Georgiev
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nicholas Favalli
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dario Neri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Gabriele Bassi, Samuele Cazzamalli or Dario Neri.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bassi, G., Cazzamalli, S., Oehler, S. et al. Response to: GCP III is not the “off-target” for urea-based PSMA-ligands. Eur J Nucl Med Mol Imaging 50, 2947–2949 (2023). https://doi.org/10.1007/s00259-023-06302-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-023-06302-4

Search

Navigation